<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909869</url>
  </required_header>
  <id_info>
    <org_study_id>H-2012-12</org_study_id>
    <nct_id>NCT01909869</nct_id>
  </id_info>
  <brief_title>A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions</brief_title>
  <acronym>CREDIT</acronym>
  <official_title>A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Medical Systems Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Medical Systems Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the purpose of this study is to assess the preliminary safety and feasibility,and to
      provide related information and evidence for the design of the further pivotal randomized
      control trial.the other purpose is to assess the performace of the stent delivery system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Single-center, prospective, pilot study

        2. De novo,coronary artery, single vessel and single lesion

        3. Sample size = 45

        4. Follow- up clinical or phone at 1-month,9-month and annually 2 to 5 years

        5. Randomization 2:1 Angio and OCT scheduled follow-up in the hospital

        6. Follow-up Angio and OCT randomized 30 patients for 4-month and 15 patiens for 12-month
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint(MACE)</measure>
    <time_frame>30days(MACE)</time_frame>
    <description>Device oriented cardiovascular endpoint at 30-day (MACE) defined as the composite of Cardiac Death,Myocardial Infarction(Q and non-Q) or Ischemia-driven Target Lesion Revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>5 years (Follow-up)</time_frame>
    <description>In-stent Late Lumen Loss at 4-month and 12-month</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Ischemia</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>EXCEL-Ⅱ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EXCEL-Ⅱ</intervention_name>
    <description>A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions</description>
    <arm_group_label>EXCEL-Ⅱ</arm_group_label>
    <other_name>CREDIT-Ⅰ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18yrs≤Age≤75yrs .

          2. De novo lesion at native coronary artery.

          3. Single target vessel and single target lesion.

          4. Lesion length ≤32mm.

          5. RVD 2.5mm～4.0mm.

          6. DS%≥70% by visual estimation.

          7. Target lesion could be covered by only one stent.

          8. Subjects are willing to follow the specified requirements follow-up.

          9. A process by which a subject voluntarily confirms his or her willingness to
             participate in a particular trial, after having been informed of all aspects of the
             trial that are relevant to the subject's decision to participate. Informed consent is
             documented by means of a written, signed and dated informed consent form.

        Exclusion Criteria:

          1. AMI within one week.

          2. CTO(TIMI0),LM lesion,ostial lesion,graft vessel lesion,bifurcation (side branch
             RVD≥2.5mm),ISR,mutivessel disease need to be treated.

          3. Severe calcified lesion unable to predilate.

          4. extremely tortuous proximal to the lesion that is inadequate to stent delivery.

          5. NYHA≥Ⅲ or LVEF≤40%.

          6. Prior stenting within 1 year.

          7. Pregnancy or lactation, and plan in postoperative pregnancy or lactation.

          8. Subjects had bleeding tendency or blood coagulation dysfunction or PCI
             contraindications, or anticoagulant therapy taboo or can't continue DAPT healers at
             least 1 year.

          9. There are other diseases (such as cancer,malignant tumor ,congestive heart
             failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin,
             etc.), scheme compliance is poor, interference related data explanation or the limited
             life (&lt; 1 year).

         10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast
             agent of one of allergy.

         11. Serious liver and kidney function is not complete person.

         12. The investigators think that do not fit to enroll the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han y ling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang J Rui</last_name>
    <phone>+86 10 68068918</phone>
    <email>jianrui.wang@jwmsgrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang G Tao</last_name>
    <phone>+86 10 68068918</phone>
    <email>gangtao.wang@jwmsgrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenyang Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Lei</last_name>
      <phone>+86 18502419715</phone>
      <email>21739982@qq.com</email>
    </contact>
    <investigator>
      <last_name>Wang Geng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MACE</keyword>
  <keyword>TVR</keyword>
  <keyword>MI</keyword>
  <keyword>TLF</keyword>
  <keyword>Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Cobalt</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

